Skip to main content

Advertisement

SpringerLink
Log in

Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Recently, based on results of the PACIFIC trial, durvalumab after chemoradiotherapy (CRT) became the standard therapy for unresectable stage III non-small cell lung cancer (NSCLC). However, in the PACIFIC trial, patients were recruited and randomized after CRT, and certain patients were considered ineligible after CRT in the real world. No study has been conducted on the patients who were ineligible for the PACIFIC trial, and hence, we conducted a retrospective study on them.

Methods

We identified 82 patients with stage III NSCLC who received definitive platinum-based concurrent CRT and had World Health Organization performance status of 0–1. We investigated the proportion, clinical characteristics, and prognoses of patients who became ineligible for the PACIFIC trial after CRT.

Results

After CRT, 19 of 82 patients (23%) became ineligible for the PACIFIC trial. Comparison between eligible and ineligible patients revealed that old age (p = 0.042), male gender (p = 0.031), and radiation therapy with V20 ≥ 35% (p = 0.032) were associated with ineligibility after CRT. Moreover, ineligible patients showed shorter PFS (6.6 vs. 15.7 months, hazard ratio [HR] 2.61, 95% confidence interval [CI] 1.16–5.89, p = 0.016) and shorter OS (18.6 vs. 44.3 months, HR 3.03, 95% CI 1.29–7.10, p = 0.007) than eligible patients.

Conclusions

Our study revealed the clinical characteristics and prognoses of patients who became ineligible for the PACIFIC trial after CRT. Physicians should be careful while prescribing CRT for patients with characteristics such as old age, male gender, and radiation therapy with V20 ≥ 35%.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30. https://doi.org/10.3322/caac.21387

    Article  PubMed  Google Scholar 

  2. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62:220–241. https://doi.org/10.3322/caac.21149

    Article  PubMed  Google Scholar 

  3. Morgensztern D, Ng S, Gao F, Govindan R (2010) Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol 5:29–33

    Article  PubMed  Google Scholar 

  4. Yoon SM, Shaikh T, Hallman M (2017) Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol 8:1–20. https://doi.org/10.5306/wjco.v8.i1.1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377:1919–1929. https://doi.org/10.1056/NEJMoa1709937

    Article  CAS  PubMed  Google Scholar 

  6. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC (2018) Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. https://doi.org/10.1056/nejmoa1809697

    Article  PubMed  Google Scholar 

  7. Vardy J, Dadasovich R, Beale P, Boyer M, Clarke SJ (2009) Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials. BMC Cancer 9:130

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Baggstrom MQ, Waqar SN, Sezhiyan AK, Gilstrap E, Gao F, Morgensztern D, Govindan R (2011) Barriers to enrollment in non-small cell lung cancer therapeutic clinical trials. J Thorac Oncol 6:98–102

    Article  PubMed  Google Scholar 

  9. Al-Baimani K, Jonker H, Zhang T, Goss GD, Laurie SA, Nicholas G, Wheatley-Price P (2018) Are clinical trial eligibility criteria an accurate reflection of a real-world population of advanced non-small-cell lung cancer patients? Curr Oncol 25:e291

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Kawachi H, Fujimoto D, Morimoto T, Ito M, Teraoka S, Sato Y, Nagata K, Nakagawa A, Otsuka K, Tomii K (2018) Clinical characteristics and prognosis of patients with advanced non-small cell lung cancer who are ineligible for clinical trials. Clin Lung Cancer. https://doi.org/10.1016/j.cllc.2018.05.014

    Article  PubMed  Google Scholar 

  11. Yamamoto N, Nakagawa K, Nishimura Y, Tsujino K, Satouchi M, Kudo S, Hida T, Kawahara M, Takeda K, Katakami N, Sawa T (2010) Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol 28:3739–3745. https://doi.org/10.1200/JCO.2009.24.5050

    Article  PubMed  Google Scholar 

  12. Carter DL, Garfield D, Hathorn J, Mundis R, Boehm KA, Ilegbodu D, Asmar L, Reynolds C (2012) A randomized phase III trial of combined paclitaxel, carboplatin, and radiation therapy followed by weekly paclitaxel or observation for patients with locally advanced inoperable non-small-cell lung cancer. Clin Lung Cancer 13:205–213. https://doi.org/10.1016/j.cllc.2011.10.005

    Article  CAS  PubMed  Google Scholar 

  13. Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, Martinez Aguillo M, Aerts J, Govindan R, Rubio-Viqueira B, Lewanski C (2016) PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide–cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 34:953–962. https://doi.org/10.1200/JCO.2015.64.8824

    Article  CAS  PubMed  Google Scholar 

  14. Steuer CE, Behera M, Ernani V, Higgins KA, Saba NF, Shin DM, Pakkala S, Pillai RN, Owonikoko TK, Curran WJ, Belani CP (2017) Comparison of concurrent use of thoracic radiation with either carboplatin–paclitaxel or cisplatin–etoposide for patients with stage III non-small-cell lung cancer. JAMA Oncol 3:1120. https://doi.org/10.1001/jamaoncol.2016.4280

    Article  PubMed  Google Scholar 

  15. Bowden JCS, Williams LJ, Simms A, Price A, Campbell S, Fallon MT, Fearon KCH (2017) Prediction of 90 day and overall survival after chemoradiotherapy for lung cancer: role of performance status and body composition. Clin Oncol 29:576–584. https://doi.org/10.1016/j.clon.2017.06.005

    Article  CAS  Google Scholar 

  16. Sanders K, Hendriks LE, Troost E, Bootsma GP, Houben R, Schols A, Dingemans AMC (2016) Early weight loss during chemoradiotherapy has a detrimental impact on outcome in NSCLC. J Thorac Oncol 11:873–879. https://doi.org/10.1016/j.jtho.2016.02.013

    Article  PubMed  Google Scholar 

  17. Topkan E, Parlak C, Selek U (2013) Impact of weight change during the course of concurrent chemoradiation therapy on outcomes in stage IIIB non-small cell lung cancer patients: retrospective analysis of 425 patients. Int J Radiat Oncol Biol Phys 87:697–704

    Article  PubMed  Google Scholar 

  18. Deek MP, Kim S, Ahmed I, Fang BS, Zou W, Malhotra J, Aisner J, Jabbour SK (2016) Prognostic impact of missed chemotherapy doses during chemoradiation therapy for non-small cell lung cancer. Am J Clin Oncol. https://doi.org/10.1097/coc.0000000000000293

    Article  Google Scholar 

  19. Shi A, Zhu G, Wu H, Yu R, Li F, Xu B (2010) Analysis of clinical and dosimetric factors associated with severe acute radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent chemotherapy and intensity-modulated radiotherapy. Radiat Oncol 5:35. https://doi.org/10.1186/1748-717X-5-35

    Article  PubMed  PubMed Central  Google Scholar 

  20. Palma DA, Senan S, Tsujino K, Barriger RB, Rengan R, Moreno M, Bradley JD, Kim TH, Ramella S, Marks LB, De Petris L (2013) Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 85:444–450. https://doi.org/10.1016/j.ijrobp.2012.04.043

    Article  PubMed  Google Scholar 

  21. Zhao Y, Chen L, Zhang S, Wu Q, Jiang X, Zhu H, Wang J, Li Z, Xu Y, Zhang YJ, Bai S (2015) Predictive factors for acute radiation pneumonitis in postoperative intensity modulated radiation therapy and volumetric modulated arc therapy of esophageal cancer. Thorac Cancer 6:49–57. https://doi.org/10.1111/1759-7714.12142

    Article  PubMed  PubMed Central  Google Scholar 

  22. National Comprehensive Cancer Network (2019) Non-small cell lung cancer (Version 3.2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed 16 Feb 2019

Download references

Acknowledgements

The authors thank Keiko Sakuragawa for her administrative assistance.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, Kobe, 650-0047, Japan

    Kazutaka Hosoya, Daichi Fujimoto, Hayato Kawachi, Yuki Sato, Mariko Kogo, Kazuma Nagata, Atsushi Nakagawa, Ryo Tachikawa & Keisuke Tomii

  2. Department of Radiation Oncology, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, Kobe, 650-0047, Japan

    Shinya Hiraoka & Masaki Kokubo

Authors
  1. Kazutaka Hosoya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daichi Fujimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hayato Kawachi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yuki Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mariko Kogo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kazuma Nagata
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Atsushi Nakagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ryo Tachikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shinya Hiraoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Masaki Kokubo
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Keisuke Tomii
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daichi Fujimoto.

Ethics declarations

Conflict of interest

Dr. Hosoya, Dr. Fujimoto, Dr. Kogo, Dr. Kokubo and Dr. Tomii received lecture fees from AstraZeneca K.K. (Tokyo, Japan). Dr. Fujimoto and Dr. Kogo received research funding from AstraZeneca K.K. (Tokyo, Japan) for separate studies. All remaining authors have no conflicts of interest to declare.

Ethical approval

All study procedures complied with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hosoya, K., Fujimoto, D., Kawachi, H. et al. Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients. Cancer Chemother Pharmacol 84, 275–280 (2019). https://doi.org/10.1007/s00280-019-03885-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-019-03885-4

Keywords

Search

Navigation